AbClon Inc.
Founded in 2010 and KOSDAQ-listed in 2017, AbClon Inc. develops the HER2-targeting antibody AC101 (HLX22) via its NEST discovery platform.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 by Korean and Swedish scientist groups and listed on KOSDAQ in 2017, AbClon Inc. is a biotech venture developing antibody therapeutics. The company operates the NEST antibody discovery platform and the AffiMab bispecific antibody platform, with its lead pipeline being the HER2-targeting antibody AC101 (HLX22). AbClon licensed AC101's China rights to Shanghai Henlius Biotech for USD 16.5 million (about KRW 18.8 billion) in 2016, transferred full global rights in 2018, and completed first-patient dosing in a global Phase 3 trial for metastatic gastric cancer in the US in July 2025.
Products & technology
- AC101 (HLX22)HER2-targeting antibody for HER2-positive gastric/GEJ cancer and breast cancer
Regulatory approvals
1 Orphan Drug designations · 2025
- OrphanNespe-cel (자가혈액유래 CD19 표적 CAR-T 세포, AT101)2025-09-17Orphan Drug designation · in development20250156335
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2021 (Phase 1/2 1)
- Phase 1/2AT1012021-12-28
7 trial sites
R&D and key agreements
Source: DART corporate disclosureAC101 (HLX22) · HER2 양성 위암·위식도접합부암(G/GEJ) · 글로벌 임상 3상(미국) · FDA approved Phase 3 IND (May 2024); Japan approved Phase 3 for metastatic gastric cancer (Oct 2024); first patient dosed in US Phase 3 (Jul 2025).
AC101 (HLX22) · HER2 저발현 유방암(엔허투 병용) · 임상 2상 · First patient dosed Apr 2025 in Phase 2 combining AC101 with Enhertu for HER2-low breast cancer.
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer1
- PerplexityPerplexityBot1
Measured since Aug 26, 2026 · 2 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition